Trial
NCT01900522
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Intervention
ITI-214 Dose A
Why stopped
Business Decision; No Safety or Efficacy Concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-02-19